Simulations Plus Collaborates with Multinational Pharmaceutical Company to Provide Modeling & Simulation Support for COVID-19 Treatment

Rhea-AI Summary

Simulations Plus, Inc. (NASDAQ: SLP) revealed its Cognigen division's collaboration with a major pharmaceutical firm to enhance the development of a COVID-19 therapy. This partnership facilitated modeling and simulation activities, significantly contributing to regulatory submissions. The project focused on real-time data processing, improving insights on pharmacokinetics and efficacy throughout clinical trials. Cognigen division president Jill Fiedler-Kelly emphasized the essential role of these services in optimizing drug development efficiency.

Positive

• Collaboration with a major pharmaceutical company on COVID-19 therapy development.
• Significant contributions to regulatory submissions through modeling and simulation.
• Real-time data processing improved understanding of pharmacokinetics and efficacy.

Negative

• None.

LANCASTER, Calif.--(BUSINESS WIRE)-- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its Cognigen division worked with a major pharmaceutical company to implement modeling and simulation activities to support the development of a candidate COVID-19 therapy. This modeling and simulation work provided significant contributions towards regulatory submissions for the compound.

Early in the COVID-19 pandemic, the pharmaceutical company initiated a collaboration to support the accelerated development of their compound. Together with scientists from the company, Sébastien Bihorel, Pharm.D., Ph.D., Senior Director of Pharmacometrics and Workflow Automation, led this cooperative team effort on behalf of Simulations Plus. Cognigen scientists provided real-time data processing and analysis, allowing for rapid knowledge updates about pharmacokinetics and efficacy in patients with COVID‑19 as the clinical trials proceeded.

“We are extremely proud of this collaboration, which further underscores the importance and critical role of modeling and simulation in informing development-related decisions and improving the efficiency of drug development,” added Jill Fiedler-Kelly, Cognigen division president.

Visit our Resource Center for more information. Contact us to learn how we can support your regulatory submissions.

About Simulations Plus
Serving clients worldwide for 25 years, Simulations Plus is a leading provider in the biosimulation market providing software and consulting services supporting drug discovery, development, research, and regulatory submissions. We offer solutions that bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com. Follow us on LinkedIn | Twitter | YouTube.

Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website to read our ESG Report.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220623005392/en/

Simulations Plus Investor Relations

Ms. Renee Bouche

661-723-7723

renee.bouche@simulations-plus.com



Hayden IR

Mr. Brian Siegel

346-396-8696

brian@haydenir.com

Source: Simulations Plus, Inc.

FAQ

What recent collaboration did Simulations Plus (SLP) announce?

Simulations Plus announced a collaboration with a major pharmaceutical company to support the development of a COVID-19 therapy.

How has the Cognigen division contributed to drug development for COVID-19 by Simulations Plus (SLP)?

The Cognigen division provided modeling and simulation activities that significantly aided regulatory submissions for the COVID-19 therapy.

What is the role of modeling and simulation in drug development according to Simulations Plus (SLP)?

Modeling and simulation play a critical role in informing development-related decisions and enhancing drug development efficiency.

What does the collaboration with the pharmaceutical company signify for Simulations Plus (SLP)?

It underscores the importance of Cognigen's modeling services in pharmaceutical development and regulatory processes.